Cytogen, Inc. (KOSDAQ:217330)

Cytogen Statistics

Total Valuation

Cytogen has a market cap or net worth of KRW 75.32 billion. The enterprise value is 58.23 billion.

Market Cap	75.32B
Enterprise Value	58.23B

Important Dates

The next estimated earnings date is Friday, November 21, 2025.

Earnings Date	Nov 21, 2025
Ex-Dividend Date	n/a

Share Statistics

Cytogen has 23.07 million shares outstanding. The number of shares has increased by 7.03% in one year.

Current Share Class	23.07M
Shares Outstanding	23.07M
Shares Change (YoY)	+7.03%
Shares Change (QoQ)	+0.35%
Owned by Insiders (%)	32.77%
Owned by Institutions (%)	n/a
Float	7.15M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.00
PB Ratio	1.81
P/TBV Ratio	2.67
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-3.82
EV / Sales	2.32
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-6.24

Financial Position

The company has a current ratio of 3.16, with a Debt / Equity ratio of 0.38.

Current Ratio	3.16
Quick Ratio	2.89
Debt / Equity	0.38
Debt / EBITDA	n/a
Debt / FCF	-1.71
Interest Coverage	-3.36

Financial Efficiency

Return on equity (ROE) is -30.41% and return on invested capital (ROIC) is -7.16%.

Return on Equity (ROE)	-30.41%
Return on Assets (ROA)	-6.16%
Return on Invested Capital (ROIC)	-7.16%
Return on Capital Employed (ROCE)	-13.89%
Revenue Per Employee	597.46M
Profits Per Employee	-362.64M
Employee Count	n/a
Asset Turnover	0.33
Inventory Turnover	8.48

Taxes

Income Tax	-809.45M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -55.51% in the last 52 weeks. The beta is -0.16, so Cytogen's price volatility has been lower than the market average.

Beta (5Y)	-0.16
52-Week Price Change	-55.51%
50-Day Moving Average	2,851.60
200-Day Moving Average	3,435.53
Relative Strength Index (RSI)	59.07
Average Volume (20 Days)	107,966

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Cytogen had revenue of KRW 25.09 billion and -15.23 billion in losses. Loss per share was -659.79.

Revenue	25.09B
Gross Profit	6.08B
Operating Income	-7.49B
Pretax Income	-16.04B
Net Income	-15.23B
EBITDA	-4.70B
EBIT	-7.49B
Loss Per Share	-659.79

Balance Sheet

The company has 33.47 billion in cash and 15.95 billion in debt, giving a net cash position of 17.51 billion or 759.15 per share.

Cash & Cash Equivalents	33.47B
Total Debt	15.95B
Net Cash	17.51B
Net Cash Per Share	759.15
Equity (Book Value)	41.66B
Book Value Per Share	1,780.08
Working Capital	29.67B

Cash Flow

In the last 12 months, operating cash flow was -7.14 billion and capital expenditures -2.19 billion, giving a free cash flow of -9.33 billion.

Operating Cash Flow	-7.14B
Capital Expenditures	-2.19B
Free Cash Flow	-9.33B
FCF Per Share	-404.43

Margins

Gross margin is 24.22%, with operating and profit margins of -29.86% and -60.70%.

Gross Margin	24.22%
Operating Margin	-29.86%
Pretax Margin	-63.92%
Profit Margin	-60.70%
EBITDA Margin	-18.74%
EBIT Margin	-29.86%
FCF Margin	n/a

Dividends & Yields

Cytogen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.03%
Shareholder Yield	-7.03%
Earnings Yield	-20.22%
FCF Yield	-12.39%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on September 28, 2022. It was a forward split with a ratio of 3.

Last Split Date	Sep 28, 2022
Split Type	Forward
Split Ratio	3

Scores

Cytogen has an Altman Z-Score of 0.94 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.94
Piotroski F-Score	4